Nyxoah SA (EBR:NYXH)
Belgium · Delayed Price · Currency is EUR 4.100
+0.100 (2.50%)
Last updated: Nov 19, 2025, 9:03 AM CET
Nyxoah Revenue
Nyxoah had revenue of 1.97M EUR in the quarter ending September 30, 2025, with 55.77% growth. This brings the company's revenue in the last twelve months to 5.64M, up 10.96% year-over-year. In the year 2024, Nyxoah had annual revenue of 4.52M with 3.98% growth.
Revenue (ttm)
5.64M
Revenue Growth
+10.96%
P/S Ratio
26.55
Revenue / Employee
30.65K
Employees
184
Market Cap
149.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.52M | 173.00K | 3.98% |
| Dec 31, 2023 | 4.35M | 1.26M | 40.99% |
| Dec 31, 2022 | 3.08M | 2.23M | 261.97% |
| Dec 31, 2021 | 852.00K | 783.00K | 1,134.78% |
| Dec 31, 2020 | 69.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 3.14B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Onward Medical | 2.72M |